Company intelligence / Profile preview
Vanquish Oncology
Champaign, Illinois, United Statesvanquishoncology.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Vanquish Oncology is developing PAC‑1 (VO‑100), an oral small molecule that activates procaspase‑3 to induce apoptosis in cancer cells. The compound is currently in Phase I clinical trials for advanced malignancies including solid tumors and neuroendocrine cancers. Early-stage results are pending; the trial is ongoing at major academic centers.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
No major pharma partnerships disclosed.
Beyond the preview
Go deeper on Vanquish Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vanquish Oncology.